Lauren Blansett
Family · Greenbrier, ARNPI 1649726845
Payments from drug & device makers
Across 494 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Pfizer$682
- Amgen$665
- Lilly USA, LLC$606
- GSK$557
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,898100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $1,255 |
| Novo Nordisk | 73 | $1,063 |
| Pfizer | 44 | $682 |
| Amgen | 37 | $665 |
| Lilly USA, LLC | 45 | $606 |
| GSK | 34 | $557 |
| AstraZeneca | 29 | $532 |
| Biohaven Pharmaceuticals, Inc. | 19 | $303 |
| Abbott | 7 | $208 |
| Corium, LLC | 8 | $184 |
| Bayer | 10 | $179 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $160 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $140 |
| Boehringer Ingelheim | 9 | $127 |
| Merck | 8 | $122 |
| Gilead | 1 | $115 |
| Johnson & Johnson | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| Antares Pharma, Inc. | 3 | $72 |
| Exact Sciences | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Currax Pharmaceuticals LLC | 3 | $48 |
| Shield Therapeutics Inc | 2 | $46 |
| Novartis | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| UCB, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Boston Scientific | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$115
How this compares
$7,899 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $77,583 |
| OzempicSemaglutide | 82 | $77,333 |
| MounjaroTirzepatide | 61 | $64,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $63,332 |
| FarxigaDapagliflozin Propanediol | 43 | $45,010 |
| LinzessLinaclotide | 38 | $26,051 |
| TrulicityDulaglutide | 17 | $21,974 |
| XareltoRivaroxaban | 14 | $15,925 |
| EliquisApixaban | 23 | $12,938 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $11,064 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $10,614 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,387 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,934 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,080 |
| Gabapentin | 158 | $2,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $606 | $86,61678 claims |
| Boehringer IngelheimJardiance | $127 | $77,58360 claims |
| Novo NordiskOzempic | $1,063 | $77,33382 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $557 | $71,719121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $532 | $51,94454 claims |
| AbbVieLinzess | $1,255 | $26,05138 claims |
| Johnson & JohnsonXarelto | $90 | $15,92514 claims |
| PfizerEliquis | $682 | $12,93823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Greenbrier
- Jarrod JerryGreenbrier$11K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.